| Identification | Back Directory | [Name]
Enfuvirtide | [CAS]
159519-65-0 | [Synonyms]
Enf
Aids059486
Aids-059486
Pentafuside
Fuzeon (tm)
Enfuvirtide
Gp41 127-162 aa
T20, Pentafuside
Enfuvirtide; T-2
Enfurvitide(T-20)
T-20 acetate salt
Well, wei peptide
Enfuvirtide impurity
Enfuvirtide USP/EP/BP
ENFUVIRTIDE(T-20) 98+%
Enfuvirtide acetate salt
Enfuvirtide(T-20) Acetate
Enfuvirtide Acetate (T-20)
Enfuvirtide & Enfuvirtide Acetate
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH{2}
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Asn-Trp-Phe-NH2
Enfuvirtide,Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2,Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2?, >95% | [EINECS(EC#)]
641-385-0 | [Molecular Formula]
C204H301N51O64 | [MDL Number]
MFCD01636054 | [MOL File]
159519-65-0.mol | [Molecular Weight]
4491.92 |
| Chemical Properties | Back Directory | [storage temp. ]
?20°C | [solubility ]
DMF: 5 mg/ml; DMSO: 5 mg/ml; PBS (pH 7.2): 2 mg/ml | [form ]
powder | [color ]
white to off-white | [Sequence]
Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys |
| Hazard Information | Back Directory | [Description]
N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-Lleucyl-
L-isoleucyl-L-glutamyl-L-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-Lglutaminyl-
L-glutaminyl-L-glutamy-L-lysyl-L-asparaginyl-L-glutamyl-L-glutaminyl-
L-glutamyl-L-leucyl-L-leucyl-L-glutamyl-L-leucyl-L-aspartyl-L-lysyl-L-tryptophyl-
L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide
Enfuvirtide is the first of a new class of HIV therapeutics that interferes with the
entry of HIV-1 by inhibiting fusion of viral and cellular membranes. It binds to the
first heptad-repeat (HR1) in ghe gp41 subunit of the viral envelope glycoprotein and
prevents the conformational changes required for the fusion with cell membranes,
thus representing a new mechanism. It is a potent inhibitor of this binding with an
IC50 in laboratory and primary isolates (HIV-1 clades A–G) ranging from 4 to
280 nM (18–1260 ng/mL), but has virtually no activity against HIV-2. Due to its
unique mechanism, it does not show cross-resistance to NRTI, NNRTI and PIs. It is
prepared by chemical synthesis, using a combination of solution and solid phase
steps. The solid phase steps utilize fmoc protection and the acid sensitive 2-
chlorotrityl chloride resin to produce peptides of lengths ranging from nine to sixteen
amino acids. These amino acids are subsequently coupled to form the full-length
peptide followed by side-chain deprotection and column chromatography. In the
HuPBMC-SCID mouse model of HIV-1 infection enfuvirtide showed a dosedependent
decrease in viral load. At doses of 200 mg/kg/day, it decreased the RNA
levels to 8.2 copies/1 million cells compared to 17 million copies/1 million cells in
the saline-treated group. In a clinical study involving 78 heavily pretreated patients
(plasma HIV RNA＞5000 copies/mL), enfuvirtide dosing of 12.5–200 mg/day by
b.i.d. subcutaneous injection resulted in a dose-dependent decrease in viral load
(plasma HIV RNA 0.3–1.6 log 10 copies/mL). In a combination drug study where all
patients received an optimized retroviral regimen with or without enfuvirtide, it was
found that, at week 24, the enfuvirtide group had a 4.5 fold-relative drop in HIV
RNA copies/mL relative to the standard treatment group. Subjects received 3–5
antiretroviral agents with or without enfuvirtide. In clinical trials, HIV-1 isolates
from 185 patients using enfuvirtide in a cocktail with other antiretroviral agents
showed 4 to 422-fold decrease in sensitivity to this drug. These more resistant types
had changes in the gp41 amino acids 36–45. Enfuvirtide is dosed twice per day
(90 mg) by subcutaneous injection and has an elimination half-life of about 3.8 h. It
is highly plasma protein bound (92%) and has a Vdss is 5.5 L. Local injection site
irritation (98% had at least one reaction), diarrhea (26.8%), nausea (20.1%), and
fatigue (16.1%) were the most common adverse events. | [Originator]
Duke University (US) | [Uses]
Antiviral (blockade of gp-41 mediated membrane
fusion). Fuzeon (Roche) [Note—The trivial name, pentafuside,
has appeared in literature. | [Definition]
ChEBI: A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutamin
l, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryp
ophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1
nfection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes. | [Brand name]
Fuzeon | [Biological Functions]
Enfuvirtide is used in combination with other antiretrovirals and works against a variety of HIV-1 variants, but it is not active against HIV-2. Resistance to enfuvirtide can develop when the virus produces changes in a 10-amino-acid domain between residues 36 to 45 in the gp41 HIV surface glycoprotein. | [Acquired resistance]
Resistance is mediated by amino acid substitutions within
the first heptad repeat region of gp41 at amino acids 36–45.
Resistance emerges fairly rapidly in patients experiencing
virological failure with an enfuvirtide-containing antiretroviral
regimen, and is associated with the return of the plasma
HIV load toward baseline within a few weeks. | [General Description]
Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus. Enfuvirtide is catabolized with the help of proteolytic enzymes. | [Pharmaceutical Applications]
A linear 36-amino acid synthetic peptide with an acetylated
N-terminus and a carboxamide C-terminus. It is formulated as a
lyophilized powder to be reconstituted for subcutaneous injection. | [Biochem/physiol Actions]
Enfuvirtide is an HIV fusion inhibitor used to patients with multi-drug resistant HIV. Enfuvirtide binds to gp41 preventing the creation of an entry pore for the HIV-1 virus. | [Pharmacokinetics]
Subcutaneous absorption c. 84.3%
Cmax 90 mg s/c twice daily c. 4.59 mg/L
Plasma half-life c. 3.8 h
Volume of distribution 5.5 L
Plasma protein binding c. 92%
Absorption and distribution
Absorption of the 90 mg dose is comparable when injected into the subcutaneous tissue of the abdomen, thigh or arm. It does not penetrate the CSF or semen. Distribution into breast milk has not been described.
Metabolism and excretion
It probably undergoes catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool. | [Clinical Use]
Treatment of HIV infection (in combination with other antiretroviral drugs)
in adults and children older than 6 years who show evidence of HIV-1
replication despite ongoing antiretroviral therapy | [Side effects]
It does not seem to have any long-term toxicities (including
the HIV lipodystrophy syndrome) associated with other
commonly used antiretrovirals. Reaction at the injection
site, variously characterized by local pain, erythema, pruritus,
induration, ecchymosis, nodules or cysts, is experienced
by more than 90% of patients and may lead to treatment
fatigue. | [Drug interactions]
Potentially hazardous interactions with other drugs
Orlistat: absorption possibly reduced by orlistat. | [Metabolism]
As a peptide, enfuvirtide is expected to undergo
catabolism to its constituent amino acids, with subsequent
recycling of the amino acids in the body pool. In vitro
human microsomal studies and in vivo studies indicate
that enfuvirtide is not an inhibitor of CYP450 enzymes.
In in vitro human microsomal and hepatocyte studies,
hydrolysis of the amide group of the C-terminus amino
acid, phenylalanine results in a deamidated metabolite.
Mass balance studies to determine elimination pathway(s)
of enfuvirtide have not been performed in humans. |
|
|